Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca M Buffa

Showing results (21-30 of 103) with videos related to

Pageof 11
Sort By:
Bioinformatics (Oxford, England)|March 4, 2025
GeneFEAST: the pivotal, gene-centric step in functional enrichment analysis interpretationAvigail Taylor, Valentine M Macaulay, Matthieu J Miossec, et al.
Pigment Cell & Melanoma Research|June 30, 2022
The MITF regulatory network in melanomaJagat S Chauhan, Michael Hölzel, Jean-Philippe Lambert, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 29, 2004
Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomasJesper G Eriksen, Francesca M Buffa, Jan Alsner, et al.
Oncotarget|August 12, 2010
Overexpression of POLQ confers a poor prognosis in early breast cancer patientsGeoff S Higgins, Adrian L Harris, Remko Prevo, et al.
Endocrinology|December 22, 2016
Vitamin D Receptor Expression in Plasmablastic Lymphoma and Myeloma Cells Confers Susceptibility to Vitamin DDuncan M Gascoyne, Linden Lyne, Hayley Spearman, et al.
Cancer Biology & Therapy|May 12, 2017
Depletion of signal recognition particle 72kDa increases radiosensitivityRemko Prevo, Gaganpreet S Tiwana, Timothy S Maughan, et al.
Oncotarget|February 19, 2015
Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancerWing-yin Leung, Ioannis Roxanis, Helen Sheldon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumabMichael I Koukourakis, Alexandra Giatromanolaki, Helen Sheldon, et al.
European Journal of Cancer (Oxford, England : 1990)|January 3, 2006
Pre-treatment proliferation and the outcome of conventional and accelerated radiotherapyGeorge D Wilson, Michele I Saunders, Stanley Dische, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapyFrancesca M Buffa, Søren M Bentzen, Frances M Daley, et al.
Pageof 11

Showing results (21-30 of 103) with videos related to

Sort By:
Pageof 11
Bioinformatics (Oxford, England)|March 4, 2025
GeneFEAST: the pivotal, gene-centric step in functional enrichment analysis interpretationAvigail Taylor, Valentine M Macaulay, Matthieu J Miossec, et al.
Pigment Cell & Melanoma Research|June 30, 2022
The MITF regulatory network in melanomaJagat S Chauhan, Michael Hölzel, Jean-Philippe Lambert, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 29, 2004
Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomasJesper G Eriksen, Francesca M Buffa, Jan Alsner, et al.
Oncotarget|August 12, 2010
Overexpression of POLQ confers a poor prognosis in early breast cancer patientsGeoff S Higgins, Adrian L Harris, Remko Prevo, et al.
Endocrinology|December 22, 2016
Vitamin D Receptor Expression in Plasmablastic Lymphoma and Myeloma Cells Confers Susceptibility to Vitamin DDuncan M Gascoyne, Linden Lyne, Hayley Spearman, et al.
Cancer Biology & Therapy|May 12, 2017
Depletion of signal recognition particle 72kDa increases radiosensitivityRemko Prevo, Gaganpreet S Tiwana, Timothy S Maughan, et al.
Oncotarget|February 19, 2015
Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancerWing-yin Leung, Ioannis Roxanis, Helen Sheldon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumabMichael I Koukourakis, Alexandra Giatromanolaki, Helen Sheldon, et al.
European Journal of Cancer (Oxford, England : 1990)|January 3, 2006
Pre-treatment proliferation and the outcome of conventional and accelerated radiotherapyGeorge D Wilson, Michele I Saunders, Stanley Dische, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapyFrancesca M Buffa, Søren M Bentzen, Frances M Daley, et al.
Pageof 11